Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-23T11:36:31.031Z Has data issue: false hasContentIssue false

RE: Clozapine-fluoxetine and the CYP450 system

Published online by Cambridge University Press:  13 June 2014

Darina Sloan
Affiliation:
University College Hospital, Galway, Ireland
James O'Boyle
Affiliation:
Consultant Psychiatrist, St Vincent's Hospital, Fairview, Dublin 3, Ireland
Rights & Permissions [Opens in a new window]

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Letter to the Editor
Copyright
Copyright © Cambridge University Press 1998

References

1.Taylor, D. Pharmacokinetic interactions involving clozapine. Br J Psychiatry 1997; 171: 109–12.CrossRefGoogle ScholarPubMed
2.Jerling, M, Lindstroin, L, Bondesson, Uet al.Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 1994; 16(4): 368–74.CrossRefGoogle Scholar
3.Pirmohamed, M, Williams, D, Madden, Set at.Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther 1995 Mar; 272(3): 984–90.Google ScholarPubMed
4.Von, Moltke LL, Greenblatt, DJ, Cotreau-Bibbo, MMet al.Inhibitors of alprzolam metabolism in vitro: effect of serotonin-reuptake inhibitor antidepressants, ketoconazole and quinidine. Br J Clin Pharmacol 1994; 36: 615–6.Google Scholar
5.Dahl, M, Llerena, A, Bondesson, Uet al.Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphism. Br J Clin Pharmacol 1994; 37: 71–4.CrossRefGoogle Scholar
6.Taylor, D (Chief Pharmacist) Bethlem and Maudsley NHS Trust, Honary Lecturer, Institute of Psychiatry (personal communication).Google Scholar